---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-26-000021"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:14:40.452934+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways 2025 net loss $287.9M; COMP360 NDA submission on track for Q4 2026

## Summary
- Full-year 2025 net loss $287.9M ($3.08/share), vs $155.1M in 2024; includes $122.6M non-cash loss on warrant liabilities.
- Q4 2025 net loss $93.9M ($1.00/share), vs $43.3M in Q4 2024.
- COMP360 in TRD: highly statistically significant Phase 3 results; FDA meeting to confirm rolling NDA submission, expected completion in Q4 2026.
- Phase 2b/3 trial in PTSD initiated after FDA acceptance of IND.
- Cash $149.6M at Dec 31, 2025; $150M Feb financing plus $200M warrant exercise extends cash runway into 2028.

## SEC filing metadata
- accession: 0001816590-26-000021
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/0001816590-26-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/cmps-20260324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-26-000021
- JSON: https://secwatch.observer/filing/0001816590-26-000021.json
- Plain text: https://secwatch.observer/filing/0001816590-26-000021.txt

## Key facts
- Earnings Releases
  COMPASS Pathways plc reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/0001816590-26-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.